What is she best known for?
The fields of study she is best known for:
- Internal medicine
- Disease
- Gene
Her main research concerns Amyloidosis, Internal medicine, AL amyloidosis, Immunology and Pathology.
The various areas that Helen J. Lachmann examines in her Amyloidosis study include Hazard ratio, Cardiology and Amyloid.
Her Internal medicine study incorporates themes from Gastroenterology and Surgery.
Helen J. Lachmann focuses mostly in the field of AL amyloidosis, narrowing it down to topics relating to Chemotherapy and, in certain cases, Thalidomide, Discontinuation and Proteasome inhibitor.
Her studies in Immunology integrate themes in fields like Canakinumab and AA amyloidosis.
Her work deals with themes such as Genetic testing, Clone and Multiple myeloma, which intersect with Pathology.
Her most cited work include:
- Natural history and outcome in systemic AA amyloidosis. (649 citations)
- Use of canakinumab in the cryopyrin-associated periodic syndrome. (644 citations)
- Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. (608 citations)
What are the main themes of her work throughout her whole career to date?
Helen J. Lachmann spends much of her time researching Internal medicine, Amyloidosis, AL amyloidosis, Pathology and Immunology.
Her Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Surgery and Cardiology.
Her research investigates the connection with Amyloidosis and areas like Transthyretin which intersect with concerns in Cardiomyopathy.
Her work carried out in the field of AL amyloidosis brings together such families of science as Melphalan, Thalidomide, Chemotherapy and Multiple myeloma.
Her Immunology study which covers Familial Mediterranean fever that intersects with MEFV.
Her AA amyloidosis research is multidisciplinary, relying on both Complication and Serum Amyloid A Protein.
She most often published in these fields:
- Internal medicine (45.54%)
- Amyloidosis (36.98%)
- AL amyloidosis (28.96%)
What were the highlights of her more recent work (between 2017-2021)?
- Internal medicine (45.54%)
- Amyloidosis (36.98%)
- AL amyloidosis (28.96%)
In recent papers she was focusing on the following fields of study:
Her main research concerns Internal medicine, Amyloidosis, AL amyloidosis, Gastroenterology and Disease.
Her research in the fields of Bortezomib, AA amyloidosis and Retrospective cohort study overlaps with other disciplines such as In patient.
Amyloidosis is the subject of her research, which falls under Pathology.
Her research integrates issues of Lenalidomide, Multiple myeloma, Chemotherapy and Transplantation in her study of AL amyloidosis.
Her Gastroenterology study combines topics in areas such as Confidence interval, Hazard ratio, Renal function, Very Good Partial Response and Natriuretic peptide.
The concepts of her Disease study are interwoven with issues in Pediatrics, Immunology, MEFV and Intensive care medicine.
Between 2017 and 2021, her most popular works were:
- A new staging system for cardiac transthyretin amyloidosis (153 citations)
- Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes (131 citations)
- The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity (123 citations)
In her most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Gene
Her primary areas of study are Amyloidosis, Internal medicine, Gastroenterology, Immunology and AL amyloidosis.
Her Amyloidosis study is concerned with Pathology in general.
Her study in Cardiac amyloidosis, Adverse effect, Familial Mediterranean fever, Retrospective cohort study and Serum amyloid A are all subfields of Internal medicine.
Her Gastroenterology research focuses on Hazard ratio and how it relates to Treatment options and Autologous stem-cell transplantation.
Her Immunology study combines topics from a wide range of disciplines, such as Canakinumab, Anakinra and Downregulation and upregulation.
Her biological study spans a wide range of topics, including Observational study, Response Duration, Chemotherapy, Survival rate and Bortezomib.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
